<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/256894-antitumor-combinations-containing-a-vegf-inhibitor-and-5fu by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 09:03:18 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 256894:ANTITUMOR COMBINATIONS CONTAINING A VEGF INHIBITOR AND 5FU</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">ANTITUMOR COMBINATIONS CONTAINING A VEGF INHIBITOR AND 5FU</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The invention concerns antitumor combinations consisting of VEGF inhibitor associated 5-flurouracil or with a 5-fluropyrimidin therapeutically useful for treating neoplastic diseases.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>WO 2006/059012	PCT/FR2005/003005<br>
1<br>
ANTITUMOR COMBINATIONS CONTAINING A VEGF-INHlBITING AGENT<br>
AND 5FU OR A DERIVATIVE THEREOF<br>
The present invention relates to combinations of a VEGF inhibitor and a<br>
chemotoxic agent of the class of 5-fluorouracil or 5-fluoropyrimidines that are useful<br>
in the treatment of neoplastic diseases.<br>
VEGF inhibitors, which are inhibitors of vascular endothelial growth factor,<br>
are, in the majority of cases, biological products chosen from soluble receptors,<br>
antisenses, RNA aptamers and antibodies. The 5-fluoropyrimidine derivatives are<br>
chosen from 5-fluorouracil, capecitabine or gemcitabine, which exhibit notable<br>
antitumoral and antileukemia properties; they are particularly useful in the treatment<br>
of ovarian cancer, breast cancer, lung cancer or colon cancer. The present<br>
combination is directed in particular toward the treatment of colon cancer or stomach<br>
cancer.<br>
The description and the preparation of the VEGF inhibitor preferably used in<br>
the invention, which is a VEGF-Trap chimeric protein, is described in patent<br>
application WO00/75319. There are several embodiments of the chimeric protein.<br>
The embodiment corresponding to VEGF-Trap is that described in Figure 24<br>
(sequence). The VEGF-Trap used in the invention is a fusion protein comprising the<br>
VEGFR1 signal sequence fused to the Ig domain D2 of the VEGFR1 receptor, itself<br>
fused to the Ig domain D3 of the VEGFR2 receptor, in turn fused to the Fc domain of<br>
IgGl, also called VEGFRlR2-FcACl orFltlD2.FK1D3.Fcâˆ†Cl.<br>
In general, the doses used, which depend on factors specific to the individual<br>
to be treated, are between 20 and 800 micrograms per kilo when the administration is<br>
carried out subcutaneously and from 2 to 20 micrograms per kilo when the<br>
administration is carried out intravenously or, optionally, intranasally at a lower dose<br>
of the order of 0.01 picogram to 1 mg per kilo.<br>
The 5-fluorouracil is generally used intravenously at a dose of between 500<br>
mg/m2 and 5000 mg/m2 per week; as regards the 5-fluoropyrimidine derivatives such<br>
as capecitabine, they are generally used, for the latter, orally at a dose of between 500<br>
and 3000 mg/m2 generally administered in two daily doses. Gemcitabine is generally<br>
used intravenously at a dose of between 500 and 2000 mg/m2 per week.<br>
An article by H Hurwitz, L Fehrenbacher, W Novotny, T Cartwright, J<br>
Hainsworth, W Heim, J Berlin, A Baron, S Griffing, E Holmgren, N Ferrara, G Fyfe,<br><br>
WO 2006/059012	PCT/FR2005/003005<br>
2<br>
B Rogers, R Ross, F Kabbinavar published in "The New England Journal of<br>
Medicine" has described a clinical trial proving a better survival rate when the<br>
combination of bevacizumab with irinotecan, 5FU and leucovorin is used compared<br>
with the same combination containing no bevacizumab. Nothing proves, in this<br>
clinical trial, that the improvement in survival rate comes from the combination of<br>
5FU with the bevacizumab; it may just as well come from the combination of<br>
irinotecan or of leucovorin with the bevacizumab, or may come from the quadruple<br>
combination. Now, as it is known that each of the anticancer agents brings, along with<br>
its therapeutic effect, toxic side effects, it appears to be opportune to limit their<br>
presence as much as possible, especially when the same effect can be obtained in the<br>
absence of at least one of them. In the present case, it is known that irinotecan leads to<br>
considerable diarrhea, which has sometimes led to the treatment having to be stopped.<br>
Furthermore, this article does not prove any synergistic effect within Corbett's<br>
meaning, i.e. an effect that cannot be obtained with each of the elements of the<br>
combination used alone at its maximum tolerated dose.<br>
It has now been found, and it is this that forms the subject of the present<br>
invention, that the effectiveness of VEGF inhibitors can be considerably improved<br>
when they are administered in combination with at least one substance therapeutically<br>
useful in anticancer treatments that has a mechanism of action different from that of<br>
the VEGF inhibitors.<br>
Moreover, since the activity of the products depends on the doses used, it is<br>
possible to use higher doses and to increase the activity by decreasing the phenomena<br>
of toxicity or delaying their appearance through the combination with the VEGF<br>
inhibitors or with their analogs of other therapeutically active substances, of growth<br>
factors of hematopoietic type, such as G-CSF or GM-CSF, or certain interleukins.<br>
More particularly, the invention relates to the combinations of VEGF-Trap<br>
with 5-fiuorouracil or derivatives thereof such as capecitabine or gemcitabine. It also<br>
relates to the combinations also including folinic acid generally combined with 5-FU.<br>
The improved effectiveness of a combination according to the invention can<br>
be demonstrated by determining the therapeutic synergism.<br>
A combination shows therapeutic synergism if it is therapeutically superior<br>
to one or other of the constituents used at its optimum dose [T.H. Corbett et al.,<br>
Cancer Treatment Reports, 66,1187 (1982)].<br>
In order to demonstrate the effectiveness of a combination, it may be<br>
necessary to compare the maximum tolerated dose of the combination with the<br><br>
WO 2006/059012	PCT/FR2005/003005<br>
3<br>
maximum tolerated dose of each of the individual constituents in the study under<br>
consideration. This effectiveness can be quantified, for example by the logjo of the<br>
killed cells, which is determined according to the following formula:<br>
log10killed cells = T-C (days)/3.32 x Td<br>
in which T-C represents the delay in growth of the cells, which is the average time, in<br>
days, for the tumors of the treated group (T) and the rumors of the control group (C)<br>
to reach a predetermined value (1 g, for example) and Td represents the time, in days,<br>
required for the volume of the tumor to double in the control animals [T.H. Corbett et<br>
al., Cancer, 40, 2660.2680 (1977) : F.M. Schabel et al., Cancer Drug Development,<br>
Part B, Methods in Cancer Research, 17, 3-51, New-York, Academic Press Inc.<br>
(1979)]. A product is considered to be active if logjo killed cells is greater than or<br>
equal to 0.7. A product is considered to be very active if the logjo killed cells is<br>
greater than 2.8.<br>
The combination, used at its own maximum tolerated dose, in which each of<br>
the constituents will be present at a dose generally less than or equal to its maximum<br>
tolerated dose, which show therapeutic synergy when the log10 killed cells is greater<br>
than the value of log10 killed cells of the best constituent when it is administered<br>
alone.<br>
The effectiveness of the combinations on solid tumors can be determined<br>
experimentally in the following way:<br>
30 to 60 mg of an MC 13/C mammary tumor fragment are transplanted<br>
bilaterally, subcutaneously, into the animals subjected to the experiment, generally<br>
mice, on day 0. The animals bearing the tumors are randomized before being<br>
subjected to the various treatments and controls. In the case of treatment to advanced<br>
tumors, the tumors are left to develop until the desired size, the animals having<br>
insufficiently developed tumors being eliminated. The animals selected are divided up<br>
randomly so as to undergo the treatments and the controls. Animals not bearing<br>
tumors can also be subjected to the same treatments as the tumor-bearing animals in<br>
order to be able to dissociate the toxic effect from the actual effect on the tumor. The<br>
chemotherapy generally begins from 3 to 22 days after the tumor transplant, according<br>
to the type of tumor, and the animals are observed every day. The various groups of<br>
animals are weighed three or four times a week until the maximum weight loss is<br><br>
WO 2006/059012	PCT/FR2005/003005<br>
4<br>
obtained, and then the groups are weighed at least once a week until the end of the<br>
trial.<br>
The tumors are measured two or three times a week until the tumor reaches<br>
approximately 2 g or until the animal's death if the latter occurs before the tumor<br>
reaches 2 g. The animals are autopsied when they are sacrificed.<br>
The antitumor activity is determined as a function of the various parameters<br>
recorded.<br>
To study the combinations on leukemias, a given number of cells are<br>
transplanted into the animals and the antitumor activity is determined by the increase<br>
in survival time of the treated mice compared with the controls. A product is<br>
considered to be active if the increased survival time is greater than 27% and it is<br>
considered to be very active if it is greater than 75% in the case of P388 leukemia.<br>
By way of examples, the following tables give the results obtained with<br>
combinations of VEGF-Trap and 5-fluorouracile used at their optimum dose.<br>
The present invention also relates to the pharmaceutical compositions<br>
containing the combinations according to the invention.<br>
The products that constitute the combination can be administered<br>
simultaneously, separately or spread out over time so as to obtain the maximum<br>
effectiveness of the combination; it being possible for each administration to have a<br>
variable duration ranging from complete rapid administration to continuous infusion.<br>
It results therefrom that, for the purpose of the present invention, the<br>
combinations are not only limited to those which are obtained by physical<br>
combination of the constituents, but also to those which allow a separate<br>
administration which may be simultaneous or spread out over time.<br>
The compositions according to the invention are preferably compositions<br>
that can be administered parenterally. However, these compositions may be<br>
administered orally.<br>
The compositions for parenteral administration are generally sterile<br>
pharmaceutically acceptable solutions or suspensions which may optionally be<br>
prepared extemporaneously at the time of use. For the preparation of nonaqueous<br>
solutions or suspensions, natural plant oils such as olive oil, sesame oil or paraffin oil<br>
or injectable organic esters such as ethyl oleate can be used. The aqueous sterile<br>
solutions may consist of a solution of the product in water. The aqueous solutions are<br>
suitable for intravenous administration insofar as the pH is suitably adjusted and<br>
isotonicity is effected, for example by means of a sufficient amount of sodium<br><br>
WO 2006/059012	PCT/FR2005/003005<br>
5<br>
chloride or glucose. The sterilization can be carried out by heating or by any other<br>
means that does not impair the composition. The combinations may also be in the<br>
form of liposomes or in the form of a combination with carriers such as cyclodextrins<br>
or polyethylene glycols.<br>
In the combinations according to the invention, file application of these<br>
constituents may be simultaneous, separate or spread out over time, it is particularly<br>
advantageous for the amount of VEGF-Trap derivative to represent from 2 to 80% by<br>
weight of the combination, it being possible for this content to vary according to the<br>
nature of the substance combined, to the desired effectiveness and to the nature of the<br>
cancer to be treated.<br>
The combinations according to the invention are particularly useful in the<br>
treatment of colon and/or stomach cancers. In particular, they may have the advantage<br>
of being able to use the constituents at doses that are much lower than those at which<br>
they are used alone.<br>
The following example illustrates a combination according to the invention.<br>
EXAMPLE<br>
Ampoules of 1 cm3 containing 25 mg of VEGF-Trap, which are diluted in a<br>
phosphate buffer, are prepared, according to the usual technique, for subcutaneous<br>
administration.<br>
0.2 ml per mouse is prepared, according to the usual technique, for<br>
intravenous administration, from a commercial solution of 5 cm containing 250 mg<br>
of 5 FU to be diluted with 5% glucose in water.<br>
These solutions are administered simultaneously, after suitable dilution, by<br>
infusion.<br>
The treatment can be repeated several times per day or per week until partial<br>
or complete remission or recovery.<br><br>
WO 2006/059012	PCT/FR2005/003005<br>
6<br><br>
Dosage in	mg/kg/day	Death due	%			<br>
(total dost	; in mg/kg)	to the	weight	% T/C	T-C	lck<br>
scVEGF-	iv5-FU	treatment	loss at		days	<br>
Trap	(day 4,11,		the			<br>
(day   4,   7,	18)		lowest			<br>
11,  14,  18,21)			point			<br>
40 (240)		0/5	2.3	4	12.7	1.4<br>
25 (150)	-	0/5	1.1	8	13.9	1.5<br>
10 (60)	-	0/5	1.1	9	12.1	1.3<br>
2.5 (15)	-	0/5	0.9	32	5.2	0.6<br>
	145 (435)	1/5	8.7	Toxic	-	-<br>
-	90 (270)	0/5	4.8	0	12.5	1.3<br>
-	55.8 (167.4)	0/5	1.1	12	7.8	0.8<br>
-	34.6 (103.8)	0/5	+ 2.3	34	4.6	0.5<br>
40 (240)	90 (270)	0/5	8.0	0	25.2	2.7<br>
25 (150)	90 (270)	0/5	9.6	0	24.8	2.7<br>
10 (60)	90 (270)	0/5	7.4	0	23.1	2.5<br>
10 (60)	55.8 (167.4)	0/5	4.4	0	16.5	1.8<br>
10 (60)	34.6 (103.8)	0/5	5.4	1	20.0	2.2<br>
2.5 (15)	90 (270)	0/5	7.0	0	20.4	2.2<br>
2.5 (15)	55.8 (167.4)	0/5	2.0	0	18.0	1.9<br>
2.5 (15)	34.6 (103.8)	0/5	2.0	6	11.7	1.3<br>
BCM-1428 (05/28/04 - 07.30.2004): tumor doubling time = 2.8 days. Average time<br>
for 750 mg on controls = 22.2 d. Treatment period = 18 d for VEGF-Trap and<br>
combination, and 15 days for 5-FU.<br>
Abbreviations used: T/C = inhibition of tumor growth at day 24, (T-C) delay of tumor<br>
growth, lck = log cells killed.<br><br>
WO 2006/059012	PCT/FR2005/003005<br>
7<br>
WHAT IS CLAIMED IS<br>
1	- Combinations containing a VEGF inhibitor with at least 5-fluorouracil or<br>
a 5-fluoropyrimidine derivative that is therapeutically useful in the treatment of<br>
neoplastic diseases.<br>
2	- Combinations containing a VEGF inhibitor with 5-fluorouracil or<br>
capecitabine or gemcitabine.<br>
3	- The combinations as claimed in claim 2, containing a VEGF inhibitor<br>
with fluorouracil.<br>
4	- The combinations as claimed in claim 3, containing a VEGF-Trap<br>
inhibitor with 5-fluorouracil.<br>
5	- The combinations as claimed in one of claims 1 to 4, characterized in that<br>
they also contain folinic acid.<br>
6	- The combinations as claimed in one of claims 1 to 5, characterized in that<br>
they contain from 2 to 80% by weight of VEGF-Trap.<br>
7	- Products containing a VEGF inhibitor and at least one therapeutically<br>
useful substance as defined in one of claims 1 to 5, in the treatment of neoplastic<br>
diseases, as a combined preparation for simultaneous use, separate use or use spread<br>
out over time in anticancer therapy.<br>
8	- Combinations containing a VEGF inhibitor with at least 5-flurorouracil<br>
or a 5-fluoropyrimidine derivative and folinic acid with the exclusion of any other<br>
chemotoxic derivative exhibiting a therapeutically synergistic effect in the treatment<br>
of neoplastic diseases.<br><br>
The invention concerns antitumor combinations consisting of VEGF inhibitor associated 5-flurouracil or with a<br>
5-fluropyrimidin therapeutically useful for treating neoplastic diseases.<br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4Njgta29sbnAtMjAwNy1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">01868-kolnp-2007-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4Njgta29sbnAtMjAwNy1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">01868-kolnp-2007-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4Njgta29sbnAtMjAwNy1jb3JyZXNwb25kZW5jZSBvdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">01868-kolnp-2007-correspondence others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4Njgta29sbnAtMjAwNy1kZXNjcmlwdGlvbiBjb21wbGV0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">01868-kolnp-2007-description complete.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4Njgta29sbnAtMjAwNy1mb3JtIDEucGRm" target="_blank" style="word-wrap:break-word;">01868-kolnp-2007-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4Njgta29sbnAtMjAwNy1mb3JtIDMucGRm" target="_blank" style="word-wrap:break-word;">01868-kolnp-2007-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4Njgta29sbnAtMjAwNy1mb3JtIDUucGRm" target="_blank" style="word-wrap:break-word;">01868-kolnp-2007-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4Njgta29sbnAtMjAwNy1ncGEucGRm" target="_blank" style="word-wrap:break-word;">01868-kolnp-2007-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4Njgta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHB1YmxpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">01868-kolnp-2007-international publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4Njgta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHNlYXJjaCByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">01868-kolnp-2007-international search report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4Njgta29sbnAtMjAwNy1vdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">01868-kolnp-2007-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4Njgta29sbnAtMjAwNy1wcmlvcml0eSBkb2N1bWVudC5wZGY=" target="_blank" style="word-wrap:break-word;">01868-kolnp-2007-priority document.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgwNS0wNi0yMDEzKS1BTUFOREVEIFBBR0VTIE9GIFNQRUNJRklDQVRJT04ucGRm" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(05-06-2013)-AMANDED PAGES OF SPECIFICATION.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgwNS0wNi0yMDEzKS1DTEFJTVMucGRm" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(05-06-2013)-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgwNS0wNi0yMDEzKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(05-06-2013)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgwOS0wNS0yMDEzKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(09-05-2013)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgxMC0wMS0yMDEyKS1BQlNUUkFDVC5wZGY=" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(10-01-2012)-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgxMC0wMS0yMDEyKS1BTUFOREVEIENMQUlNUy5wZGY=" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(10-01-2012)-AMANDED CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgxMC0wMS0yMDEyKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(10-01-2012)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgxMC0wMS0yMDEyKS1ERVNDUklQVElPTiAoQ09NUExFVEUpLnBkZg==" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(10-01-2012)-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgxMC0wMS0yMDEyKS1GT1JNLTEucGRm" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(10-01-2012)-FORM-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgxMC0wMS0yMDEyKS1GT1JNLTEzLnBkZg==" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(10-01-2012)-FORM-13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgxMC0wMS0yMDEyKS1GT1JNLTIucGRm" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(10-01-2012)-FORM-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgxMC0wMS0yMDEyKS1GT1JNLTMucGRm" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(10-01-2012)-FORM-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgxMC0wMS0yMDEyKS1GT1JNLTUucGRm" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(10-01-2012)-FORM-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgxMC0wMS0yMDEyKS1PVEhFUiBQQVRFTlQgRE9DVU1FTlQucGRm" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(10-01-2012)-OTHER PATENT DOCUMENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgxMC0wMS0yMDEyKS1PVEhFUlMucGRm" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(10-01-2012)-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgxOS0wNi0yMDEyKS1BQlNUUkFDVC5wZGY=" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(19-06-2012)-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgxOS0wNi0yMDEyKS1BTUFOREVEIENMQUlNUy5wZGY=" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(19-06-2012)-AMANDED CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgxOS0wNi0yMDEyKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(19-06-2012)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgxOS0wNi0yMDEyKS1ERVNDUklQVElPTiAoQ09NUExFVEUpLnBkZg==" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(19-06-2012)-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgxOS0wNi0yMDEyKS1GT1JNLTEucGRm" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(19-06-2012)-FORM-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgxOS0wNi0yMDEyKS1GT1JNLTIucGRm" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(19-06-2012)-FORM-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgxOS0wNi0yMDEyKS1PVEhFUlMucGRm" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(19-06-2012)-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgyMC0wMi0yMDEyKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(20-02-2012)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgyMC0wMi0yMDEyKS1GT1JNLTMucGRm" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(20-02-2012)-FORM-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LSgyMC0wMi0yMDEyKS1QRVRJVElPTiBVTkRFUiBSVUxFIDEzNy5wZGY=" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-(20-02-2012)-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LUFTU0lHTk1FTlQucGRm" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-ASSIGNMENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1LT0xOUC0yMDA3LUNPUlJFU1BPTkRFTkNFIDEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">1868-KOLNP-2007-CORRESPONDENCE 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg2OC1rb2xucC0yMDA3LWZvcm0gMTgucGRm" target="_blank" style="word-wrap:break-word;">1868-kolnp-2007-form 18.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="256893-a-method-for-adjusting-a-feedforward-filter-and-a-decision-feedback-equalizer.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="256895-method-for-notifying-arrival-of-fax-documents.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>256894</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1868/KOLNP/2007</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>32/2013</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>09-Aug-2013</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>07-Aug-2013</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>24-May-2007</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>AVENTIS PHARMA S. A.</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>20 AVENUE RAYMOND ARON, F-92160, ANTONY</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>VRIGNAUD, PATRICIA</td>
											<td>27 RUE DE LA CLAIRIERE F-77380, COMBS LA VILLE</td>
										</tr>
										<tr>
											<td>2</td>
											<td>BISSERY, MARIE-CHRISTINE</td>
											<td>5 RUE HENRI POINCARE F-94400, VITRY SUR SIENE</td>
										</tr>
										<tr>
											<td>3</td>
											<td>FURFINE, ERIC</td>
											<td>2055, QUAKER RIDGE ROAD, CROTON ON HUDSON, 10520, NEW-YORK</td>
										</tr>
										<tr>
											<td>4</td>
											<td>HOLASH, JOCELYN</td>
											<td>321, CHANNING WAY, ALAMEDA, 94502, CALIFORNIA</td>
										</tr>
										<tr>
											<td>5</td>
											<td>CEDARBAUM, JESSE M.</td>
											<td>28 PRYER MANOR ROD, LARCHMONT, 10538, NEW-YORK</td>
										</tr>
										<tr>
											<td>6</td>
											<td>CHIRON-BLONDEL, MARIELLE</td>
											<td>13 RUE DE CASTAGNARY, F-75015, PARIS</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K 38/17</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/FR2005/003005</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2005-12-02</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>04/12,870</td>
									<td>2004-12-03</td>
								    <td>France</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/256894-antitumor-combinations-containing-a-vegf-inhibitor-and-5fu by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 09:03:19 GMT -->
</html>
